Cagrilintide vs Selank
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Selank
Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia for anxiety and cognitive enhancement.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Selank |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Modulates the expression of brain-derived neurotrophic factor (BDNF) and affects serotonin and norepinephrine systems. Has immunomodulatory and anxiolytic properties. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Intranasal administration: 250-500mcg 2-3 times daily. Subcutaneous: 250-500mcg daily. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Most commonly administered intranasally for cognitive effects. Can also be injected subcutaneously. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Generally well-tolerated. Some users report mild fatigue or nasal irritation with intranasal use. |
| Best For |